Who is eligible for clinical trial NCT06784167?

Participants must meet protocol criteria for Chronic Lymphocytic Leukemia. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT06784167 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2025-09-08

Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment (NCT06784167)

🟢 Recruiting Interventional Protocol 📊 Observational Clinical Research Sponsor: OHSU Knight Cancer Institute

🩺 Plain-English Summary (8th-Grade Level)

This study evaluates immune responses after CAR-T therapy to find out if CAR-T therapy reduces the effectiveness of the vaccines (vaccine immunity) against diseases such as measles, mumps and rubella, among others in patients with multiple myeloma and non-Hodgkin lymphoma.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (6 items) and avoid the listed exclusions (3 items).

Location: OHSU Knight Cancer Institute — Portland, Oregon

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

\* Willingness to provide written informed consent before any study-specific procedures or activities are performed
Age ≥ 18 years of age, at the time of consent
Documented, histologically or cytologically confirmed diagnosis of multiple myeloma (MM), diffuse large B cell lymphoma (DLBCL),follicular lymphoma (FL), mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), or small lymphocytic lymphoma (SLL), or primary mediastinal B cell lymphoma (PMBL). All number of prior lines of therapy are allowed
History of prior vaccination against common VPD
Approved by managing physician for CAR-T therapy, with preparative conditioning planned within the next 90 days
Approved by managing physician for revaccination against Streptococcus pneumoniae or tetanus

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
\* Ongoing use of immunosuppressive agents or plans for immunosuppressive therapy that would interfere with interpretation of study endpoints
Uncontrolled, intercurrent illness including, but not limited to, systemic infection, symptomatic congestive heart failure, unstable angina pectoris, or psychiatric illness/social situations that would limit compliance with study requirements or make the study procedures unadvisable

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

OHSU Knight Cancer Institute — Portland, Oregon

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

🏛️ View Official NIH Record ↗